TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9272102
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) replacement (both doses)
Study: 9272102
Drug: Patients continuing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients continuing GH therapy
Study: 8257527
Drug: Somatostatin analog
Normalized name: Somatostatin analog
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin analog SMS 201-995 (SMS) at doses ranging from 0.8-2.2 micrograms/kg sc
Study: 8257527
Drug: Somatostatin analog
Normalized name: Somatostatin analog
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin analog SMS 201-995 (SMS) at standard doses of 1 microgram/kg sc
Study: 3001518
Drug: Intranasal alpha
Normalized name: alpha tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal alpha 2-interferon
Study: 25940353
Drug: School-based scheme
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-based scheme for diagnosis and treatment of schistosomiasis mansoni
Study: 25940353
Drug: Community-based scheme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based scheme for diagnosis and treatment of schistosomiasis mansoni
Study: 25940353
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of positives for Schistosoma mansoni with praziquantel
Study: 25940353
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of positives for soil-transmitted helminthes (STH) with mebendazole
Study: 23080288
Drug: Hib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hib plus MCC vaccine
Study: 21134613
Drug: Collagenase (0.58
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagenase (0.58 mg)
Study: 18197912
Drug: IL-8 measurement
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-8 measurement in pleural fluid at a cutoff value of 1000 pg/mL
Study: 18197912
Drug: CRP measurement
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP measurement in pleural fluid at a cutoff value of 80 mg/L
Study: 17313855
Drug: PEG-rhG-CSF 100
Normalized name: PEG-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-rhG-CSF 100 microg/kg (single subcutaneous injection on day 3)
Study: 17313855
Drug: rhG-CSF 5
Normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rhG-CSF 5 microg x kg(‐1) x d(‐1) (daily subcutaneous injection starting on day 3 for 14 days)
Study: 14728105
Drug: Baclofen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (20 mg t.i.d.)
Study: 11022077
Drug: Increased Lp(a)
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased Lp(a) level (>30 mg/dL)
Study: 8828247
Drug: medication only,
Approvals — FDA: no, EMA: no, PMDA: no
Description: medication only, no contingencies
Study: 1441947
Drug: Growth hormone-loaded
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone-loaded PMMA (20 mg of growth hormone)
Study: 1441947
Drug: Cemented or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cemented or cementless hip replacement without added growth hormone (Control)
Study: 15936468
Drug: Glimepiride (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (doses equivalent to gliclazide 40 mg = glimepiride 1 mg, glibenclamide 2.5 mg = glimepiride 2 mg)
Study: 15936468
Drug: Conventional SU
Normalized name: Sus scrofa skin
DrugBank: Sus scrofa skin (DB10606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional SU (gliclazide or glibenclamide, no change in treatment)
Study: 8874326
Drug: IFN alpha
Normalized name: alpha tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN alpha 2a (9 million IU) subcutaneously three times weekly with 5‐FU (750 mg/m2/d) by continuous intravenous infusion on days 1 to 5 and then weekly IV bolus at the same dose
Study: 8874326
Drug: 5‐FU alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU alone at the same dose schedule
Study: 1642918
Drug: Crystalloid preload
Normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalloid preload 20 ml kg‐1 over 10 min
Study: 1642918
Drug: Crystalloid preload
Normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalloid preload 20 ml kg‐1 over 20 min
Study: 24650832
Drug: Behavioral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral placebo treatment (BPT)
Study: 16531614
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (0.8 mg) + Vitamin B12 (0.4 mg)
Study: 16531614
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (0.8 mg) + Vitamin B12 (0.4 mg) + Vitamin B6 (40 mg)
Study: 10694782
Drug: Cocoa butter
Normalized name: Cocoa Butter
DrugBank: Cocoa butter (DB11086)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa butter (30.7 g/d) consumed in the form of black chocolate
Study: 9380281
Drug: Cisapride (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (10 mg, single oral dose)
Study: 8096475
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no oxytocin infusion)
Study: 2864051
Drug: Nadolol 80
Normalized name: nadolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol 80 mg once daily
Study: 28105902
Drug: Adjunctive porcine
Normalized name: Secretin porcine
DrugBank: Secretin porcine (DB09527)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive porcine small intestine submucosa (SIS; Oasis Ultra)
Study: 24162940
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ibuprofen and paracetamol
Study: 19466669
Drug: Ephedrine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine (50 mg taken 1 hour prior to sexual activity)
Study: 19466669
Drug: SSRIs (sertraline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRIs (sertraline, paroxetine)
Study: 19466669
Drug: SSRIs (fluoxetine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRIs (fluoxetine)
Study: 15199624
Drug: SQNYCH combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQNYCH combined with chemotherapy
Study: 15199624
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine only
Study: 336002
Drug: L-5-hydroxytryptophan (L-5-HTP)
Normalized name: L-5-HTP
DrugBank: Oxitriptan (DB02959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-5-hydroxytryptophan (L-5-HTP) in combination with Benzerazide
Study: 26247351
Drug: Micro-capsules containing
Normalized name: fenofibrate Oral Capsule [Lipantil Micro]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micro-capsules containing menthol/PCL
Study: 22975664
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and clopidogrel plus cilostazol (intensification group, n = 72)
Study: 22975664
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and clopidogrel (control group, n = 74)
Study: 22975664
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and clopidogrel plus cilostazol (intensification group)
Study: 19558562
Drug: 5-ASA (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-ASA (1.5 g for 1 year)
Study: 16122956
Drug: Valdecoxib (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valdecoxib (40 mg) given orally for 4 days prior to oesophageal acid infusion
Study: 16122956
Drug: IV Parecoxib
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: IV Parecoxib (40 mg) given 120 min after oesophageal acid infusion
Study: 16122956
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo given orally for 4 days prior to oesophageal acid infusion
Study: 16122956
Drug: Saline given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline given IV 120 min after oesophageal acid infusion
Study: 15513550
Drug: Daily nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily nasal spray with physiological saline
Study: 11176172
Drug: Normal monocytes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal monocytes incubated with septic serum and anti-IL-10 antibodies
Study: 11176172
Drug: Normal monocytes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal monocytes incubated with anti-TGF-beta antibodies
Study: 9316690
Drug: Flunarizine (FZ)
Normalized name: flunarizine
DrugBank: Flunarizine (DB04841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine (FZ) 20 mg
Study: 9316690
Drug: Cinnarizine (CZ)
Normalized name: cinnarizine
DrugBank: Cinnarizine (DB00568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnarizine (CZ) 150 mg
Study: 2898422
Drug: olsalazine 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: olsalazine 500 mg bd
Study: 2898422
Drug: sulphasalazine 1
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sulphasalazine 1 g bd
Study: 30780126
Drug: Diet and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet and metformin therapy
Study: 23737342
Drug: Chemotherapy combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy combined with targeted arterial infusion of verapamil
Study: 23737342
Drug: Chemotherapy combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy combined with targeted arterial infusion of verapamil in patients with liver metastases
Study: 17873673
Drug: Oxygenated glycerol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygenated glycerol triester (OGT) oral spray (1 or 2 sprays up to 4 times daily)
Study: 17873673
Drug: Oxygenated glycerol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygenated glycerol triester (OGT) oral spray
Study: 15689192
Drug: Sumatriptan nasal
Normalized name: SUMAtriptan nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan nasal spray administered 120 min after the onset of the attack
Study: 9918893
Drug: Celiprolol 200
Normalized name: celiprolol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol 200 mg daily
Study: 2316840
Drug: Inhaled nebulisation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nebulisation using a jet nebuliser
Study: 2316840
Drug: Cricothyroid injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cricothyroid injection
Study: 7309300
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg dihydroxydibutylether (DHBE)
Study: 17708159
Drug: Cold blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold blood cardioplegia solution with PA vent and PEEP during CPB
Study: 12677762
Drug: Elastic compression
Normalized name: elastin
DrugBank: Elastin (human) (DB15364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elastic compression therapy (group B)
Study: 21697300
Drug: High antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: High antioxidant spice blend (14 g) added to a 5060‐kJ (1200 kcal) meal
Study: 17085985
Drug: Statin drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin drugs for lowering cardiovascular risk
Study: 8378854
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 125 mg/day and curantyl (150‐225 mg/day) from gestation week 12‐19 till delivery
Study: 3005377
Drug: Ciprostene at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprostene at a maximum dose of 160 ng/kg/min for 8 hours daily for three days.
Study: 29362248
Drug: Narrative medicine-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrative medicine-based intervention (three 30 min talks with GPs over 12 months)
Study: 29362248
Drug: Narrative medicine-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrative medicine-based intervention
Study: 26406216
Drug: PA lumbar
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PA lumbar mobilization plus traditional treatment (Ultrasonic and Infra-red)
Study: 26406216
Drug: Placebo mobilization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo mobilization plus traditional treatment
Study: 21413975
Drug: n-3 LC-PUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 LC-PUFA supplements
Study: 10551191
Drug: Regular telephone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular telephone contact with a diabetes nurse educator for advice about adjustment of insulin therapy
Study: 1662671
Drug: Herpes simplex
Normalized name: herpes simplex 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herpes simplex type I subunit vaccine
Study: 6133637
Drug: Prazosin, 14.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin, 14.0 +/- 2.4 mg/day in three equal doses
Study: 26150543
Drug: Placebo arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo arm of a randomized clinical trial of Chinese medicine
Study: 20222930
Drug: Cold atmospheric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold atmospheric argon plasma treatment (5 min daily) in addition to standard wound care
Study: 12410058
Drug: Olanzapine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (up to 30 mg per day)
Study: 12410058
Drug: Olanzapine (high-dose)
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine (high-dose)
Study: 2496619
Drug: Flumazenil (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (0.3 mg)
Study: 2496619
Drug: Midazolam-Ringer's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam-Ringer's solution
Study: 901629
Drug: Hypolipidaemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypolipidaemic therapy
Study: 29535259
Drug: High-frequency oscillating
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-frequency oscillating device for respiratory muscle training (8 weeks, 3 times daily)
Study: 26316701
Drug: Test ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Test ondansetron oral soluble film formulation
Study: 26316701
Drug: Reference ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reference ondansetron oral soluble film formulation
Study: 23852061
Drug: Nitrous oxide/oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrous oxide/oxygen inhalation sedation and local anesthesia
Study: 18503607
Drug: Glyburide co-administered
Normalized name: Glyburide
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide co-administered with Sitagliptin
Study: 14618045
Drug: Sotalol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol (80 mg two times daily for five days starting from the morning of the first postoperative day)
Study: 14618045
Drug: Magnesium (1.5
Normalized name: bicarb dialy soln 11 without K calcium (2.5 mEq/L)-magnesium (1.5 mEq/L) HEMODIALYS SOLUTION, NON-ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium (1.5 g daily for six days starting in the operating room just before cardiopulmonary bypass)
Study: 3435920
Drug: Methotrexate (MTX),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (MTX), 40 mg/m2 iv push weekly
Study: 3435920
Drug: Sequential Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sequential Methotrexate and 5-fluorouracil (MTX 150 mg/m2 iv for 1 h; 5-FU 600 mg/m2 iv for 2 h; leucovorin rescue 10 mg/m2 iv and orally every 6 h 4 times, repeated every 10 days)
Study: 25950425
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules and normal saline infusion perioperatively (control)
Study: 25950425
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules and lidocaine 1 mg/kg intravenous bolus dose followed by 2 mg/kg/h infusion until skin closure
Study: 25950425
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg oral pregabalin and normal saline infusion perioperatively
Study: 25950425
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg oral pregabalin and lidocaine 2 mg/kg/h infusion until skin closure
Study: 10570388
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream (dosed twice daily, once daily, and 3 times weekly)
Study: 10570388
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream (dosed twice weekly)
Study: 10570388
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream (dosed once weekly)
Study: 8932457
Drug: Test suspensions
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test suspensions
Study: 1881558
Drug: Picotamide (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Picotamide (900 mg/die)
Study: 7051249
Drug: Trimethoprim-sulfamethoxazole (TMP-SMZ)
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMZ) 160 mg of TMP plus 800 mg of SMZ daily for four months
Study: 31470971
Drug: Passive intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Passive intervention group (PG) - oral health-related information and activity record cards
Study: 24340770
Drug: Medication based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication based on antlers of Siberian stags
Study: 19833861
Drug: Laropiprant with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laropiprant with extended-release niacin
Study: 19833861
Drug: Extended-release niacin
Normalized name: niacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release niacin alone
Study: 15154607
Drug: 2.0 g
Normalized name: Fifty50 2.0 Glucose Meter
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 g daily GLA (borage oil)
Study: 10631624
Drug: Doxazosin 2
Normalized name: doxazosin 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin 2 mg tablet
Study: 9181630
Drug: Trazodone (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone (50, 100 and 200 mg)
Study: 9181630
Drug: Triazolam (0.125,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.125, 0.25, 0.50 mg)
Study: 1373007
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline solution (7.5% NaCl)
Study: 2857210
Drug: Hydrochlorothiazide 50
Normalized name: hydrochlorothiazide 50 MG
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide 50 mg twice a day
Study: 2857210
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hydrochlorothiazide and propranolol
Study: 28515369
Drug: Aggressive lipid-
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive lipid- and blood pressure-lowering therapy
Study: 18319412
Drug: Gemcitabine (30-minute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (30-minute infusion of 1000 mg/m2 once per week for 3 weeks prior to chemoradiation and for 12 weeks after chemoradiation)
Study: 18319412
Drug: Fluorouracil (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorouracil (continuous infusion of 250 mg/m2 per day for 3 weeks prior to chemoradiation and for 12 weeks after chemoradiation)
Study: 16870074
Drug: 12 μg/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 μg/h fentanyl transdermal system (fentanyl TTS)
Study: 9050128
Drug: Neuroleptic doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroleptic doses
Study: 3532010
Drug: Aerosolized metaproterenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized metaproterenol (second treatment)
Study: 29860500
Drug: Intralipid/heparin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid/heparin infusion
Study: 23969265
Drug: 100 kVp
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 kVp protocol with 20% reduced contrast dose
Study: 22107850
Drug: MenACWY‐TT and
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY‐TT and HepA/B (Twinrix) co-administered
Study: 10634681
Drug: Intensive prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive prevention (counseling, F‐varnish applications, F‐lozenges, sealants, chlorhexidine)
Study: 360903
Drug: 5% ribavirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% ribavirin in ointment base
Study: 31424713
Drug: Halobetasol 0.01%/Tazarotene
Normalized name: HALOBETASOL 0.01%/TAZAROTENE 0.045% LOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halobetasol 0.01%/Tazarotene 0.045% lotion (HP/TAZ)
Study: 8466427
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group (E) - vinyl urinary bags reused for 4 weeks with daily decontamination using dilute bleach rinse
Study: 8466427
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (C) - vinyl urinary bags replaced weekly
Study: 3026052
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (40 mg orally four times daily)
Study: 3026052
Drug: Tamoxifen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (10 mg orally twice daily)
Study: 30734195
Drug: Pyloric injection
Normalized name: Helicobacter pylori
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyloric injection of magnesium sulfate-lidocaine mixture
Study: 30734195
Drug: Pyloric injection
Normalized name: Helicobacter pylori
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyloric injection of normal saline (control)
Study: 10075322
Drug: Partially defatted
Normalized name: rice bran, defatted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partially defatted flaxseed (approximately 50 g partially defatted flaxseed/d)
Study: 1898585
Drug: Mupirocin intranasally
Normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mupirocin intranasally twice daily for 5 days